 |
Partner Level: Innovator |
| Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries. | |
Company Websitehttps://www.certara.com/Partner EventsLive Trivia Networking SessionThursday, March 17 1:30 - 2:00pm ET Project Optimus: A Zoomside Chat Brought to you by Certara Thursday, March 17 2:05 - 2:15pm ET |
Connect with Certara EmployeesPatrick Smith, PharmD - PresidentLinkedIn - Patrick.smith@certara.com Julie Bullock, PharmD - Vice President, Global Head of Clinical Pharmacology & Translational Medicine LinkedIn - Julie.bullock@certara.com Rajesh Krishna, PhDm MBA - Senior Director LinkedIn - Rajesh.krishna@certara.com |
 |
Partner Level: Innovator |
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. |
|
Company Websitewww.gilead.comPartner EventsSpeed MentoringWednesday, March 16 12:00 - 1:00pm ET Daily Welcome & Overview Thursday, March 17 10:00 - 10:15am ET Clinical Pharmacology at Gilead: Where Every Unique Perspective is Welcomed Thursday, March 17 4:20 - 4:35pm ET Student/Trainee Communication Showdown Friday, March 18 2:30 - 3:30pm ET Poster Walk: Advancing Precision Medicine Through Inclusion & Diversity Friday, March 18 5:30 - 6:00pm ET |
Sandhya Ramanathan Girish, PhD - VP, Clinical Pharmacology |
 |
Partner Level: Innovator |
In Pfizer Clinical Pharmacology, we use innovative methods to integrate knowledge of PK, PD, patient characteristics and disease biology to inform clinical development strategy, study designs and dosage regimen selection. The outcome will be efficient drug development, rational decisions and optimal therapy for patients. |
|
Company Websitehttps://www.pfizer.com/Partner EventsRole of MIDD: A Zoomside Chat Brought to you by PfizerThursday, March 17 2:20 - 2:25pm ET Pfizer Micro-Recruitment Session Thursday, March 17 4:40 - 4:55pm ET |
Brian Corrigan, PhD - Global Head, Clinical Pharmacology |
 |
Partner Level: Advocate |
For more than 40 years, Genentech has been dedicated to rigorous and groundbreaking science, developing therapies for unmet medical needs. Today, the Genentech Research and Early Development organization shapes the future of medicine by discovering and developing life-changing therapies through pioneering science in the areas of oncology, immunology, ophthalmology, neuroscience and infectious disease. The Genentech Research and Early Development organization aspires to make fundamental scientific discoveries and to develop these discoveries into first or best-in-class medicines made in the best interest of our patients. To reach these goals, we actively encourage creativity, discussion and leadership among our researchers, welcoming the diverse skills and backgrounds each member brings to the team. What does it take to work in the Genentech Research and Early Development organization? Find out more by getting to know our scientists. Interested in learning how our Oncology Biomarker team is using real-time human clinical data to directly inform new discoveries? Learn more here about Reverse Translation. |
|
Company Websitehttps://www.genentech.comPartner EventsFail Fest Networking SessionWednesday, March 16 2:30 - 3:00pm ET |
Connect with Genentech EmployeesNastya Kassir, PharmD, PhD - Director M&S, Principal ScientistEric Reyner, BS - Senior Principal Scientific Researcher |
 |
Partner Level: Advocate |
Merck is a research-driven biopharmaceutical company. Our mission is built on the simple premise that if we “follow the science” that great medicines can make a significant impact to our world. We believe that a research-driven enterprise dedicated to world-class science can succeed by inventing medicine and vaccine innovations that make a difference for patients across the globe. We are known as Merck & Co., Inc., in the United States and Canada and MSD everywhere else. For more than a century, we have been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, our company continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. In a world of rapid innovation, we seek brave Inventors who want to make an impact in all aspects of our business, enabling breakthroughs that will affect generations to come. We encourage you to bring your disruptive thinking, collaborative spirit and diverse perspective to our organization. Learn more about our Quantitative Pharmacology & Pharmacometrics organization, hear from our scientists and see current availably opportunities here. |
|
Company Websitehttps://www.merck.com/Partner EventsQuantitative Approaches Within Infectious Disease: A Zoomside Chat Brought to you by MerckWednesday, March 16 5:20 - 5:25pm ET Welcome & Overview Friday, March 18 12:15 - 12:30pm ET |
Connect with Merck EmployeesPrajakti Kothare, PhD - Associate Vice President, Quantitative Pharmacology & PharmacometricsLinkedIn - prajakti.kothare@merck.com Matthew Rizk, PhD - Executive Director, Quantitative Pharmacology & Pharmacometrics LinkedIn - matthew.rizk@merck.com Bela Patel, PhD - Executive Director, Quantitative Pharmacology & Pharmacometrics LinkedIn - bela.patel@merck.com |
 |
Partner Level: Advocate |
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. |
|
Company Websitehttps://www.janssen.comPartner EventsSpeed Mentoring: Colleague to ColleagueFriday, March 18 3:45 - 4:45pm ET |
Connect with Janssen EmployeesVivaswath Ayyar, PhD - Sr. Scientist, PharmacometricsLinkedIn - vayyar@its.jnj.com Daniele Ouellet, PhD - Vice President, Global Head CPP LinkedIn - douelle2@its.jnj.com Nahor Haddish-Berhane, PhD - Senior Director, CPP Oncology LinkedIn - nhaddish@its.jnj.com |
 |
Partner Level: Supporter |
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia and Edinburgh, UK. InSysBio was founded in 2004 and has an extensive track record of supporting pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio team has developed and constantly updates its own QSP infrastructure that includes both services and software products. Software represents QSP-platforms that are systematized databases of a specific disease, where all data is annotated and described by equations. A user can create an appropriate model in a few clicks, by selecting the required parameters. InSysBio’s QSP software is developed for both internal and external usage and allows to create modeling projects or even advisory applications. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit insysbio.com. |
|
Company Websitehttp://insysbio.com/Partner EventsInSysBio Micro-Theater: The Second Life of In Vitro DataThursday, March 17 3:45 - 4:00pm ET |
Connect with InSysBio EmployeesOleg Demin, PhD - CEOLinkedIn - demin@insysbio.com Maria Mironovich - Business Development Manager LinkedIn - mironovich@insysbio.com |
 |
Partner Level: Contributor |
Company Websitehttps://www.bms.com/ |
Connect with Bristol-Myers Squibb EmployeesTBDLinkedIn - Email |
 |
Partner Level: Contributor |
Excelra empowers innovation in life sciences across the value chain from discovery to market leveraging its globally leading data and analytics solutions. Our Clinical Trial Outcomes Data (CTOD) and ClinPharm solutions help our pharma and biotech clients make informed decisions. We provide custom scientific data curation services to assist teams like Pharmacometrics by developing databases for Model-Based Meta-Analysis, Pharmacokinetics, and Pharmacodynamics, Disease modeling. Quantitative Systems Pharmacology, Trial simulation analysis, and other modeling and simulation business cases. In near two decades of service, we helped our clients by developing indication-specific and/or drug-specific summary level databases for drug development analysis, efficacy safety, toxicokinetics, clinical trial simulation requirements, library indexing, and data exploratory visualization from public libraries and proprietary data sources. Excelra has been the preferred data and analytics partner to over 160 global clients, including 16 of the top 20 large Pharma. Know More>> https://www.excelra.com/clinical/#clinical_pharmacology |
|
Company Websitehttps://www.excelra.com/ |
Connect with Excelra EmployeesSuraj Bhansali, PhD - Associate VPLinkedIn - suraj.bhansali@excelra.com Chinmayee Jadhav, MS - Program Manager LinkedIn - chinmayee.jadhav@excelra.com Abhishek Nainani, B.Pharm - Deputy GM, Business Development LinkedIn - abhishek.nainani@excelra.com |
 |
Partner Level: Contributor |
Metrum Research Group, established in 2004, is a global leader in biomedical modeling and simulation. We have provided strategic decision making for more than 200 companies on over 800 projects. We support our clients in advancing drug development programs by supplying them with the highest quality scientific expertise. Our offerings include strategic modeling and simulation services, solutions, and education. We are a team of experienced scientists, technologists, and support staff, passionate about enabling informed biomedical decision-making through data-driven quantitative methods. We are inspired and driven by the goal of improving health and defeating disease, particularly where there are unmet needs. For more information, visit www.metrumrg.com. |
|
 |
Partner Level: Contributor |
Initially established as a specialized clinical pharmacology research institution in 1986, SOUSEIKAI has grown into the largest early phase specialty clinical trial site in Japan. Supporting both domestic and global pharma, biotech, and medical device development, we strive to pursue science-driven early phase studies to help best support our clients. As clinical pharmacology specialists having conducted research with various Asian populations, we are able to assess important ethnic differences, helping streamline and facilitate the clinical development process between regions simultaneously, resulting in quicker access to safe and innovative treatments globally. |
|
Company Websitehttps://www.souseikaiglobal.com |
Connect with Sousekai EmployeesNozomu Miyawaki - Senior Manager of Global Business DevelopmentLinkedIn - nozomu-miyawaki@lta-med.com Andrew Melli - Senior Manager LinkedIn - andrew-melli@lta-med.com Akira Fujie - Global Clinical Development LinkedIn - akira-fujie@lta-med.com |
 |
|
 |
Partner Level: Contributor |
Spaulding Clinical is a full-service, state-of-the-art and fully paperless Phase I clinical pharmacology unit. We specialize in IND-enabling clinical pharmacology studies, cardiovascular safety, and clinical proof of concept. We provide expertise on study design, offering in-house medical writing, clinical data management, biostatistics, project management, clinical laboratory, and PK/PD analysis. With a focus on the highest quality data, the highest standards of safety, and the most advanced technology the market has to offer, Spaulding Clinical delivers a truly unique clinical research solution. Our commitment to quality goes beyond the simple acquisition of data. We employ proven processes rooted in a rigorous quality management system that encompasses every aspect of our organization, ensuring the highest standards in the industry. Data has the potential to be compromised by human error, both when entered into systems by staff or during handoffs. Because Phase I studies start and are executed 40% faster than all other phases, you need a team and systems that understand these nuances. At Spaulding Clinical, we were the first and the only organization to have built an integrated eSource/data management system from the ground up that essentially eliminates human transcription along with the need for data handoffs to other vendors. |
|
Company Websitewww.SpauldingClinical.com |
Connect with Spaulding Clinical EmployeesCassandra Erato - CEOLinkedIn - Cassandra.Erato@SpauldingClinical.com Randy Spaulding - Founder, Chairman, Chief Visionary Officer LinkedIn - Randy.Spaulding@SpauldingClinical.com Lee Barsky - Vice President of Global Sales LinkedIn - lee.Barsky@SpauldingClinical.com |
 |
Partner Level: Contributor |
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. At Takeda, the mission of Quantitative Clinical Pharmacology (QCP) is to enable rational dose selection through quantitative integration of pharmacokinetics, pharmacodynamics, safety, efficacy and sources of variability across patient populations, throughout the development lifecycle of our medicines. Our scientist’s work in therapeutically aligned R&D organization representing QCP in global product teams through the lifecycle of a program. Our scientists demonstrate excellence in applying quantitative approaches to critical decisions in R&D and are significant contributors to the design, informativeness and efficiency of clinical programs. |
|
Company Websitehttps://www.takeda.com/en-us/Partner EventsTakeda Micro-Recruitment SessionFriday, March 18 12:00 - 12:15pm ET |
John Gibbs, PhD - Lead Scientist |
 |
Partner Level: Contributor |
At Travere Therapeutics we are in rare for life. We come together every day to help patients, families and caregivers as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent and we work with the rare disease community to identify, develop and deliver life-changing therapies. We continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. Company Websitehttps://travere.com/ |
|
.png)